Uncategorised - European Medical Journal

Rituximab in Adults with Autoimmune Haematological Disorders

Rituximab, a monoclonal anti-CD20 antibody, has proven to be an excellent therapeutic agent for haematological diseases. Low-dose…

Long-Term Outcomes After Allo-HSCT in ALL

Patients (pts) with acute lymphoblastic leukaemia (ALL) in difficult first complete remission (CR) or in second CR, and…

Putting Patients First in Haematology

During the Specialized Working Group session, ‘Quality of Life and Symptoms: Promoting Connection Between Patients and Clinicians’, which…

100 Years of von Willebrand Disease

von Willebrand disease (VWD) is considered the most common inherited bleeding disorder, even surpassing haemophilia A. Nevertheless, VWD…

Microfluidic Testing in Patients with BDUC

In 40–70% of patients referred to a haematologist for the evaluation of an increased bleeding tendency, no diagnosis can…

EHA 2025 Highlights in Acute Lymphoblastic Leukemia

The most important advances in Ph-negative ALL come from the incorporation of immunotherapy into first-line ALL. In this sense…

Synchronous Twin Malignancies in a Young Female: A Case Report

Synchronous twin malignancies, defined as the simultaneous occurrence of two distinct primary cancers in the same patient, represent a…

Advancing Frontiers in Myeloproliferative Neoplasms

THE 30th EUROPEAN Hematology Association (EHA) Congress marked a pivotal year in advancing the treatment and understanding…

Lenzilumab and Azacitidine Combination Therapy in Proliferative CMML

Chronic myelomonocytic leukaemia (CMML) is a rare cancer orchestrated by granulocyte-macrophage colony-stimulating factor (GM-CSF)…

MRD in Clinical and Regulatory Decisions

THE EUROPEAN Hematology Association-European Medicines Agency (EHA2025-EMA) Joint Symposium on minimal residual disease (MRD)…